Respiratory Medicine
Volume 104, Issue 10 , Pages 1396-1403 , October 2010

Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD

  • Antonio Anzueto

      Affiliations

    • Department of Medicine, Pulmonary Disease, 111E, 7400 Merton Minter Boulevard, The University of Texas Health Science Center at San Antonio, South Texas Veterans Health Care System, San Antonio, TX 78229, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 210 617 5256; fax: +1 210 949 3006.
    • ,
  • Marc Miravitlles

      Affiliations

    • Fudació Clínic. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Catalonia, Spain

Received 28 October 2009 ,Accepted 26 May 2010.

References 

  1. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF the Chronic Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can Respir J. 2003;10:248–258
  2. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852
  3. Soler-Cataluña JJ, Martinez-Gracía MA, Roman Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931
  4. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow-up study. Thorax. 2004;59:387–395
  5. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient’s perception of exacerbations of COPD—the PERCEIVE study. Respir Med. 2007;101:453–460
  6. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:554–564
  7. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204
  8. Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, et al. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruc Pulmon Dis. 2008;3:803–814
  9. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;17:380S–385S
  10. Papi A, Bellettato CNM, Braccioni F, Romangoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121
  11. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46
  12. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638–1645
  13. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113:1542–1548
  14. Seemungal TAR, Harpe-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 2000;16:677–683
  15. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613
  16. Snow V, Lascher S, Mottur-Pilson C for the Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians–American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001;134:595–599
  17. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345–1352
  18. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD?. Ther Adv Respir Dis. 2007;1:61–76
  19. O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J. 2007;14(Suppl. B):5B–32B
  20. Miravitlles M, Monso E, Mensa J, Aguarón Pérez J, Barberán J, Bárcena Caamaño M, et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol. 2008;44:100–108
  21. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138–1180
  22. Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med. 2005;118(7A):39S–44S
  23. Garcia-Vidal C, Almagro P, Romani V, Rodriguez-Carballeira M, Cuchi E, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34(5):1072–1078
  24. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:853–860
  25. Obaji A, Sethi S. Acute exacerbations of chronic bronchitis. What role for the new fluoroquinolones?. Drugs Aging. 2001;18:1–11
  26. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G. Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62:442–450
  27. Chodosh S, Deabate CA, Haverstock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med. 2000;94:18–27
  28. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother. 2008;9:1755–1772
  29. Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G on behalf of the SMART Study Group. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 2002;14:597–608
  30. Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin Ther. 2006;28:1175–1180
  31. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–593
  32. Wilson R, Allegra L, Huchon G, Izquierdo J-L, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953–964
  33. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. for the PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–2598
  34. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PMM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008;63:415–422
  35. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin–clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin–clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrobial Agents Chemother. 2005;49:153–160
  36. Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr Med Res Opin. 2005;21:245–254
  37. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503–512
  38. Martinez FJ, Grossman RF, Zadeikis N, Fisher AC, Walker K, Ambruzs ME, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J. 2005;25:1001–1010
  39. Urueta-Robledo J, Ariza H, Jardim JR, Caballero A, Garcia-Calderon A, Amabile-Cuevas CF, et al. the MOX-CB Study Group Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med. 2006;100:1504–1511
  40. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2004;23:129–137
  41. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2007;29:56–61
  42. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP for the MOSAIC Study Group. Antibiotic treatment and factors influencing short and long-term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006;61:337–342
  43. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med. 2004;98:697–707
  44. Wilson R, Schentag JJ, Ball P, Mandell L for the 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639–652
  45. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C the 070 Clinical Study Group. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother. 2000;12:314–325
  46. Miravitlles M, Zalacain R, Murio C, Ferrer M, Alvarez-Sala JL, Masa JF, et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials. Clin Drug Investig. 2003;23:439–450
  47. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J for the EFEMAP Study Group. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med. 2005;99:955–965
  48. Schaberg T, Möller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides. Clin Drug Investig. 2006;26:733–744
  49. Marketing authorization application withdrawn for Factive (gemifloxacin). http://www.nelm.nhs.uk/en/NeLM-Area/News/2009—June/24/Marketing-authorisation-application-withdrawn-for-Factive-gemifloxacin-/Available at:Accessed 5.02.10

PII: S0954-6111(10)00254-4

doi: 10.1016/j.rmed.2010.05.018

Respiratory Medicine
Volume 104, Issue 10 , Pages 1396-1403 , October 2010

Article Tools

* Image Usage & Resolution